What Is Livagen?
Livagen is the name used for an experimental four-amino-acid peptide usually identified as lysine-glutamic acid-aspartic acid-alanine, abbreviated KEDA. It belongs to the Russian short-peptide bioregulator programme and was designed after analysis of peptide material derived from liver tissue.
Its evidence is laboratory-heavy. Published work includes rat liver explants, cultured rat hepatocytes, digestive-enzyme experiments, human serum tested outside the body and human lymphocytes grown in culture. A later review describes animal liver-disease experiments, but much of the underlying work is difficult to evaluate independently from the accessible primary reports.
No published controlled study was identified in which people received Livagen as a treatment. Claims that it detoxifies the liver, reverses fibrosis, treats hepatitis or slows human ageing are therefore unsupported.
What is Livagen made from?
The sequence reported in the originating literature is:
`Lys-Glu-Asp-Ala (KEDA)`
These names refer to lysine, glutamic acid, aspartic acid and alanine. A tetrapeptide contains four amino-acid residues linked by three peptide bonds. Lysine has a positively charged side chain under many biological conditions, while glutamic acid and aspartic acid are usually negatively charged.
Researchers described producing KEDA by directed chemical synthesis after analysing amino acids in liver-derived polypeptide preparations. This makes Livagen different from Ventvil and other animal-tissue extracts discussed in the same research programme. A defined synthetic sequence and a mixture extracted from liver are not interchangeable interventions.
Why is Livagen associated with the liver?
The development programme began with low-molecular-weight peptide fractions isolated from animal organs. Researchers later proposed short sequences intended to reproduce selected effects of those fractions. Livagen was assigned to liver research through that process.
The liver performs hundreds of functions, including processing nutrients, making blood proteins, modifying hormones and medicines, producing bile and removing some waste products. Calling a peptide a “liver bioregulator” does not show that it travels selectively to hepatocytes, the principal functional cells of the liver.
Tissue targeting would require measurements of intact KEDA in blood and organs, evidence of entry into relevant liver cells and comparison with exposure elsewhere. No human distribution study provides those data.
What did the organotypic liver-culture study find?
A 2001 paper tested Cortagen, Epithalon, Livagen and Vilon in organotypic cultures from different rat tissues. An organotypic culture keeps small fragments of tissue alive outside the body and preserves more local organisation than a flat layer of one cell type.
Livagen stimulated the growth zone around rat liver explants. The authors interpreted the pattern across the four peptides as evidence of tissue-specific activity because each compound produced its reported effect in the tissue associated with its development.
An enlarged growth zone is a broad laboratory measurement. It may reflect cell movement, proliferation or extension of cellular processes. It does not show that the new material forms normally organised liver tissue, produces useful proteins, clears toxins or restores blood flow. The removed tissue also cannot answer questions about absorption, metabolism or whole-body toxicity.
What did the functional-morphology experiment examine?
A later paper examined the structure and function of cell populations in an organotypic liver culture exposed to Livagen. The investigators used morphometry, which means quantitative measurement of shapes and structures, together with immunocytochemistry, a staining method that uses antibodies to locate particular proteins in cells.
The authors concluded that the tetrapeptide stimulated structural and functional homeostasis in the culture. Homeostasis means maintenance of a relatively stable internal state. The phrase is broad and should not be read as proof that a damaged liver was restored.
Without a living circulation, immune system and bile drainage, an explant models only a narrow part of liver biology. The study can generate hypotheses about cell populations but cannot demonstrate treatment of hepatitis, fatty liver disease, fibrosis or liver failure.
How did Livagen affect protein synthesis?
Researchers cultured hepatocytes from rats aged between one and 24 months and measured short biological rhythms in protein synthesis. Hepatocytes make albumin, clotting proteins, transport proteins and many enzymes, so protein production is central to liver function.
The study reported that Livagen increased protein synthesis in cells from rats of different ages, with the largest effect in old animals. It also increased the amplitude of fluctuations in old-rat cultures. Epitalon, used as a comparison peptide associated with the pineal gland, did not produce the same change.
This comparison supports sequence-dependent activity under the reported conditions, but it leaves major questions. Total protein synthesis does not reveal which proteins increased. More protein production could represent useful function, a stress response or altered cell growth. The study did not show that the cultures corrected a disease or that KEDA would reach human liver cells at the same concentration.
Does a greater effect in old rat cells mean anti-ageing activity?
No. Older cells may begin with lower protein synthesis or respond differently to culture conditions, creating more room for a measured increase. A larger laboratory response does not show reversal of biological age.
Ageing involves accumulated molecular damage, altered immunity, metabolic change, loss of tissue reserve and increased disease risk across the body. A temporary change in protein production in removed rat cells addresses only one measurement. It does not establish healthier ageing, a longer lifespan or preserved human function.
An anti-ageing claim would need defined outcomes, comparison groups, long follow-up and independent replication. Human studies would need to show a clinically meaningful benefit rather than movement in a molecular marker. Livagen has not met that standard.
What did the digestive-enzyme study show?
A rat study examined Livagen and enzyme activity in the gastrointestinal tract and other organs at different ages. The authors reported that Livagen was only weakly hydrolysed and that small-intestinal peptide hydrolases did not appreciably break it down in their experimental system. Hydrolases are enzymes that split chemical bonds using water.
This result is sometimes used to imply oral bioavailability, but enzyme resistance in an assay is not the same as absorption. A peptide taken by mouth must also remain stable in stomach acid, cross the intestinal lining, avoid extensive metabolism and enter circulation in an intact form. Each step needs direct measurement.
The study also examined changes in digestive-enzyme activity, but these remain animal biochemical endpoints. They do not establish improved digestion or liver health in people.
What was tested in human serum?
Researchers added Livagen and Epitalon to human serum in a laboratory assay and measured enzymes that break down enkephalins. Enkephalins are naturally produced opioid peptides involved in pain signalling and other physiological processes.
Livagen inhibited enkephalin-degrading enzymes, with a reported half-maximal inhibitory concentration of 20 micromolar. This concentration, often written IC50, is the amount associated with a 50 per cent reduction in enzyme activity under the assay conditions. Livagen did not bind detectably to mu or delta opioid receptors in rat brain-membrane preparations.
Although human serum was used, this was not a human treatment study. Serum removed from the body lacks circulation, organs and feedback systems. The experiment does not show that people receiving Livagen would reach the reported concentration or experience pain relief, mood effects, liver benefit or any other clinical outcome.
What are the chromatin studies?
Chromatin is the combination of DNA and packaging proteins inside the nucleus. Tightly packed heterochromatin is generally less accessible to the machinery that transcribes genes into RNA. Deheterochromatinisation means that some of this material becomes less condensed.
Researchers cultured lymphocytes from older people with Livagen and reported decondensation in selected chromosomal regions. Lymphocytes are white blood cells involved in immune responses. Related work reported reactivation of ribosomal genes, which help cells make the molecular machinery required for protein synthesis.
These experiments used cells taken from people but did not administer Livagen to people. Opening chromatin is not automatically beneficial. Cells normally switch regions between more and less accessible states, and widespread disruption could be harmful. The papers do not show a specific liver target, durable correction of ageing or improvement in health.
What about chromosome fragile sites?
Chromosome fragile sites are regions that can appear as gaps or constrictions when cells undergo particular forms of DNA-replication stress. They are laboratory indicators of chromosome instability, not a diagnosis on their own.
A study exposed cultured lymphocytes from people of different ages and from patients with breast cancer to metal ions and peptide bioregulators, including Livagen. The authors examined whether the peptides changed the expression pattern of fragile sites.
This design is far removed from treating cancer or preventing mutation in a person. It involves an artificial cell-culture challenge, and a shift in visible chromosome features does not establish reduced cancer incidence. Livagen should not be described as an anti-cancer treatment from this work.
Does Livagen bind directly to DNA?
The broader short-peptide programme proposes that peptides enter the nucleus and interact with particular DNA sequences. Computational docking has been used to model how peptides might fit around DNA. Docking is a computer-based prediction of possible molecular arrangements, not direct observation inside a living cell.
Chromatin changes are compatible with many explanations. Livagen might act indirectly through enzymes, signalling pathways, metabolism or cellular stress. The published studies do not establish a receptor, a direct binding site or a complete chain from KEDA exposure to improved liver function.
A convincing mechanism would require physical binding measurements, sequence controls, concentration-response experiments and tests showing that blocking the proposed interaction removes the effect. It would also need to explain activity in lymphocytes and serum when Livagen is described as liver-associated.
What liver-disease experiments have been reported?
A 2020 review from the originating research network describes KEDA and a liver polypeptide complex in experimental models of fibrosis, acute hepatitis and chronic hepatitis. Fibrosis is the accumulation of scar tissue after repeated injury. Hepatitis means inflammation of the liver and can arise from viruses, alcohol, metabolic disease, medicines, toxins or autoimmune activity.
The review reports normalisation of liver, immune and antioxidant measurements. However, a review summary is not a substitute for complete primary reports showing animal numbers, allocation, masking, exclusions, effect sizes and statistical analysis. It also discusses KEDA alongside Ventvil, making careful separation of the synthetic peptide from the tissue-derived mixture essential.
These claims should be treated as preliminary preclinical reporting. They do not establish benefit in human hepatitis or fibrosis.
Has Livagen been tested in humans?
No published controlled human treatment study was identified through October 2026. Laboratory experiments using human serum or cultured human lymphocytes are sometimes described loosely as human research, but participants did not receive Livagen in those studies.
There is no Phase I trial defining initial safety, tolerability and pharmacokinetics. Pharmacokinetics describes absorption, distribution, chemical breakdown and clearance. There is also no controlled evidence for liver enzymes, liver fat, fibrosis, symptoms, hospital admission, transplantation or survival.
What would credible liver evidence require?
Investigators would first need a chemically verified KEDA product and assays capable of distinguishing intact peptide from its amino acids and metabolites. Early studies would establish exposure and safety before testing people with a defined condition.
The trial outcome would depend on the disease. Blood concentrations of alanine aminotransferase and aspartate aminotransferase can indicate liver-cell injury, but their improvement does not always prove reversal of disease. Imaging can estimate liver fat or stiffness. Biopsy can assess inflammation and fibrosis but involves removing a small tissue sample and has sampling limitations.
Patient-centred outcomes might include symptoms, progression to cirrhosis, liver failure, transplantation and survival. Random allocation, a suitable placebo or standard-care comparison, masking and prespecified analysis would reduce bias. None of this clinical evidence exists for Livagen.
Does Livagen “detox” the liver?
“Detox” is too vague to be a scientific outcome. The liver transforms many substances through defined enzyme systems, while the kidneys, lungs and gastrointestinal tract also remove waste. A treatment claim should state which compound is cleared, by what pathway and with what measurable health benefit.
No human study shows that Livagen accelerates removal of alcohol, medicines, environmental chemicals or metabolic waste. Increasing general protein synthesis in rat cells does not demonstrate detoxification. People concerned about a poisoning or medicine-related liver injury need medical assessment, not an unapproved peptide.
What is known about safety?
There is no adequate human safety record. Short length does not guarantee safety, and ordinary amino-acid composition does not predict the effect of the intact sequence. Potential studies would need to examine immune reactions, blood chemistry, liver and kidney function, effects on other organs and interactions with medicines.
Chromatin and protein-synthesis findings create additional questions about off-target activity. A compound intended to change gene accessibility or cellular production would require careful assessment of unwanted proliferation and long-term effects. These are uncertainties rather than documented Livagen adverse reactions.
Product quality is separate from molecular risk. A label cannot prove sequence, content, sterility or freedom from bacterial endotoxins. Endotoxins are inflammatory components of certain bacteria and can remain even when living organisms are absent. A stated purity percentage does not establish pharmaceutical quality.
How is Livagen synthesised and checked?
KEDA can be assembled through solid-phase peptide synthesis. Protected amino acids are coupled in the specified order while the growing chain remains attached to a resin. Temporary protecting groups limit unwanted reactions. The peptide is then released, deprotected and purified.
Mass spectrometry can confirm molecular mass, while fragmentation can add sequence information. Chromatography separates the desired tetrapeptide from shortened chains and related impurities. Further analysis may measure peptide content, counterions, water, residual solvents and stability.
Material for regulated sterile research would also require batch consistency, potency, particle, sterility and endotoxin controls. This is a non-procedural explanation of quality assessment, not a production guide.
How was Livagen developed?
| Period | Development |
|---|---|
| 1970s onward | Soviet and Russian researchers investigated tissue-derived peptide preparations |
| Later development | KEDA was synthesised after analysis of liver polypeptide material |
| 2001 to 2005 | Papers reported rat liver-culture, hepatocyte and digestive-enzyme findings |
| 2002 to 2008 | Cultured human lymphocyte and chromosome studies examined chromatin changes |
| 2020 | A review summarised proposed liver, immune and ageing effects |
| Through October 2026 | No published controlled human treatment trial was identified |
Is Livagen approved?
No. Livagen is not approved by the United States Food and Drug Administration, the United Kingdom Medicines and Healthcare products Regulatory Agency or the European Medicines Agency.
How strong is the evidence overall?
| Question | Best available evidence | Defensible conclusion |
|---|---|---|
| Does Livagen affect cultured rat liver tissue? | Several cell and explant experiments | Selected growth and protein measures changed |
| Does it alter cultured human cells? | Lymphocyte chromatin experiments | Chromatin measurements changed outside the body |
| Does it treat animal liver disease? | Review-level preclinical reporting | Preliminary and incompletely documented |
| Does it improve human liver disease? | No treatment trial | Unknown |
| Does it slow human ageing? | No clinical outcome study | Not established |
| Is it safe in people? | No adequate exposure study | Unknown |
| Is it approved? | No FDA, MHRA or EMA approval | No |
Frequently asked questions
What is Livagen?
It is an experimental four-amino-acid peptide associated with liver research.
What is its sequence?
It is usually reported as Lys-Glu-Asp-Ala, abbreviated KEDA.
Does Livagen repair the liver?
No human evidence demonstrates liver repair.
Does it treat fatty liver or hepatitis?
No controlled human trial has tested either claim.
Is Livagen a detox product?
No study shows that it removes toxins from people.
Has Livagen been studied in human material?
Yes, in serum and cultured lymphocytes outside the body. Those experiments were not human treatment trials.
Does it slow ageing?
Laboratory findings in older cells do not establish slower human ageing.
Has it been tested in people?
No published controlled human treatment study was identified.
Is Livagen known to be safe?
No adequate human safety profile exists.
Is Livagen approved?
It is not approved by the FDA, MHRA or EMA.
Sources
Research reviewed through October 2026.